OmniAb, Inc.
NASDAQ:OABIBiotechnology
+$0.16 today
- Market cap
- $740.97M
- Beta
- 1.15
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.42
Volume 1.22M
Average 0.67M
OABI Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
OmniAb, Inc.NASDAQ: OABI
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $3.94M, compared with $0 a year earlier.
Context
- Short-term debt amounted to 1.3% of total assets at the end of Q1 FY2026, up 1.3 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 3.88M USD
- Year-over-year change
- —
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.88M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Debt vs competitors
How OABI compares with its peers on the latest reported figures
- OABI's Mar 2026 short-term debt of $3.94M is the 2nd highest of the 4 companies compared; the peer median is $2.27M.
- Short-term debt amounts to 1.3% of total assets for OABI, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $5.21M | — | +3.1% | 2.4% | |
| Mar 2026 | $3.94M | — | — | 1.3% | |
| Mar 2026 | $2.27M | -10.8% | -33.3% | 1.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding OABI) | $2.27M | -10.8% | -15.1% | 1.2% | |
Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 33.39M | 16.36M | 27.6M | 25.52M |
| Short-term Investments | 0 | 54.88M | 70.63M | 31.84M | 28.5M |
| Net Receivables | 21.14M | 30.29M | 3.84M | 5.27M | 7.39M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.41M | 6.4M | 4.07M | 3.43M | 3.93M |
| Total Current Assets | 22.54M | 124.95M | 94.9M | 68.14M | 65.34M |
| Property, Plant & Equipment (Net) | 20.13M | 41.46M | 38.13M | 33.28M | 24.97M |
| Goodwill | 83.98M | 83.98M | 83.98M | 83.98M | 83.98M |
| Intangible Assets | 176.32M | 167.24M | 155.47M | 138.06M | 125.15M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.5M | 3.58M | 2.75M | 2.1M | 1.47M |
| Total Non-current Assets | 281.92M | 296.26M | 280.32M | 257.42M | 235.57M |
| Total Assets | 304.47M | 421.21M | 375.23M | 325.56M | 300.91M |
| Account Payables | 2.92M | 2.97M | 4.41M | 2.3M | 1.88M |
| Short-term Debt | 0 | 0 | 0 | 0 | 3.88M |
| Tax Payables | 0 | 3.49M | 0 | 0 | 0 |
| Deferred Revenue | 10.79M | 8.21M | 6.85M | 2.34M | 3.16M |
| Other Current Liabilities | 4.92M | 8.18M | 7.8M | 6.67M | 7.34M |
| Total Current Liabilities | 20.58M | 26.02M | 23.12M | 15.09M | 16.25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 21.96M | 21.34M | 11.35M | 2.31M | 785K |
| Deferred Revenue (Non-current) | 9.23M | 4.33M | 862K | 117K | 0 |
| Other Non-current Liabilities | 5.12M | 4.14M | 3.23M | 1.04M | 393K |
| Total Non-current Liabilities | 49.58M | 53.82M | 37.52M | 22.85M | 17.63M |
| Total Liabilities | 70.16M | 79.84M | 60.64M | 37.94M | 33.89M |
| Common Stock | 0 | 12K | 12K | 12K | 14K |
| Retained Earnings | 0 | 11.25M | (39.37M) | (101.4M) | (166.18M) |
| Accumulated OCI | 234.31M | 9K | 50K | 27K | 12K |
| Other Stockholders Equity | 234.31M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 234.31M | 341.37M | 314.59M | 287.62M | 267.03M |
| Total Debt | 13.85M | 25.8M | 25.56M | 23.16M | 20.33M |
| Net Debt | 13.85M | (7.59M) | 9.2M | (4.43M) | (5.19M) |
OmniAb, Inc.
NASDAQ:OABI
Intrinsic Alpha fair value
Locked
Current Price
$5.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.